Aptinyx Inc. announced positive top-line results from a 23-patient, single-blind, Phase 2 study of its novel NMDA receptor modulator, NYX-2925, in patients with fibromyalgia. Administration of NYX-2925 resulted in statistically significant effects on the primary endpoint, brain activity biomarkers associated with central pain processing, measured using advanced imaging techniques. Clinically meaningful improvements were also observed on secondary patient-reported endpoints, including pain scores...